- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02688374
A Bioequivalence Study of Three, 2 mg Nicotine Chewing Gums (Two Tests and One Reference) in Healthy Adult Smokers
December 18, 2017 updated by: GlaxoSmithKline
A Single-Dose, Open-Label, Three-way Crossover Bioequivalence Study of Three, 2 mg Nicotine Chewing Gums (Two Tests and One Reference) in Chinese Male Healthy Adult Smokers
This is a randomized, open-label, single-dose, three-period, crossover, single-center comparative bioavailability (BA) study under fasting condition in Chinese healthy male adult participants with a history of cigarette smoking.
The participants will be admitted to the investigational clinic at least 38 hours before dosing and will remain domiciled until the completion of all study procedures at approximately 24 hours after dosing.
Three toothpastes (one is commercial non-medicated non-nicotine containing chewing gum and other two are nicotine containing gums) will be provided across the 3 treatment periods.
During each of the 3 treatment periods, participants will be under supervision in a non-smoking area and will abstain from smoking.There will be a total of at least 7 days and not more than 10 days (clinical furlough period) between treatment periods.
Twenty (20) blood samples will be collected for pharmacokinetic (PK) analysis at baseline and multiple time points following study drug administration.
The trial duration will be approximately 49 days and up to 55 days from screening to study end including the screening period.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
45
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Beijing, China, 100032
- GSK Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Participants must understand and provide written informed consent before any assessment is performed, understand the study procedures, and be willing to complete the required assessments and the study.
- Chinese male participants between 18 and 45 years of age (inclusive) in general good physical health as judged by the Investigator.
- Normal vital signs as follows:
- Oral body temperature between 35.0 and 37.5 ºC (95 and 99.5 F) inclusive
- Supine systolic blood pressure between 90 and 140 mmHg inclusive
- Supine diastolic blood pressure between 55 and 90 mmHg inclusive
- Pulse rate between 50 and 100 beats per minute (bpm) inclusive
- History of cigarette smoking of at least 10 cigarettes per day continuously for the past 3 months prior to screening.
- Body weight ≥ 50 kg, Body Mass Index (BMI) between 19 and 28 at screening.
- Ability to communicate and comply with all study requirements including the study specific chewing and swallowing procedures.
Exclusion Criteria:-
- Use of other investigational drugs within 30 days or 10 half-lives of enrollment, whichever is longer.
- History of or known hypersensitivity to the study drug or excipients.
- Diagnosis of long QT syndrome or QTc > 450 msec for males at screening.
- Any surgical or medical condition which may significantly alter the absorption, distribution, metabolism or excretion of any drug substance.
- History of malignancy or neoplastic disease of any organ system treated or untreated, orthostatic hypotension, cardiovascular disease, stroke, TIA, fainting or blackouts, clinically significant metabolic, pulmonary, neurological, hematological, autoimmune, psychiatric or endocrine disorders.. within the past 5 years prior to screening.
- Any evidence of cardiovascular, pulmonary, renal, hepatic, gastrointestinal, hematological, endocrinological, metabolic, autoimmune, neurological, psychiatric, other diseases or other clinically significant laboratory findings at screening.
- Participant has used any medication within two weeks before first scheduled study drug administration or within less than 10 times the elimination half-life of the respective drug.
- Unable to comply with the chewing and/or swallowing rhythm requirements (> 5% deviation of the total counts over 30 minutes) after trying either one of the two training sessions for 3 times.
- CO > 12 ppm after at least 38 hours confinement period in clinics prior to first dosing.
- Participants reports consumption of any drug metabolizing enzyme inducing or inhibiting aliments, evidence of current alcohol abuse or reports consumption exceeding 35 g of pure alcohol per day.
- Any history of drug hypersensitivity, asthma, urticaria, or other significant allergic diathesis, positive results in any of the virology tests for Human immunodeficiency virus (HIV)-Ab, Hepatitis C virus (HCV)-Ab, Surface antigen of the hepatitis B virus (HBs-Ag), and Tp-Ab.
- Participation in a previous clinical study with or without another investigational product and with ~470 ml blood drawn, or blood donation within the last 3 months prior to screening or previous enrollment into the current study.
- Vulnerable individual
- Inability to be venipuncture and/or tolerate venous access, unwilling to accept slight irritation of the throat and increased salivation due to nicotine gum administration.
- Unable or unwilling to discontinue the use or consumption of cigarette smoking, any nicotine containing products, Oral, local or topical pharmaceutical agents, consumption of caffeine/theophylline - containing products, grapefruit, Seville orange, orange, lemon, lime, apple, and pineapple, performance of unaccustomed strenuous physical exercise.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Treatment A:Treatment B:Treatment C
Participants will be administered with Treatment A(Nicorette 2 mg coated mint gum) followed by Treatment B (Nicotinell 2 mg coated mint gum) followed by Treatment C (Nicotinell 2 mg coated fruit flavor gum).
Administration of each treatment will be separated by clinical furlough period of at least 7 days and not more than 10 days.
|
Participants will be administered with 2 mg coated mint gum of Nicorette
Participants will be administered with 2 mg coated mint gum of Nicotinell
Participants will be administered with 2 mg coated fruit flavor gum of Nicotinell
|
Other: Treatment B:Treatment C:Treatment A
Participants will be administered with Treatment B (Nicotinell 2 mg coated mint gum) followed by Treatment C (Nicotinell 2 mg coated fruit flavor gum) followed by Treatment A(Nicorette 2 mg coated mint gum).
Administration of each treatment will be separated by clinical furlough period of at least 7 days and not more than 10 days.
|
Participants will be administered with 2 mg coated mint gum of Nicorette
Participants will be administered with 2 mg coated mint gum of Nicotinell
Participants will be administered with 2 mg coated fruit flavor gum of Nicotinell
|
Other: Treatment C:Treatment A:Treatment B
Participants will be administered with Treatment C (Nicotinell 2 mg coated fruit flavor gum) followed by Treatment A(Nicorette 2 mg coated mint gum) followed by Treatment B (Nicotinell 2 mg coated mint gum).
Administration of each treatment will be separated by clinical furlough period of at least 7 days and not more than 10 days.
|
Participants will be administered with 2 mg coated mint gum of Nicorette
Participants will be administered with 2 mg coated mint gum of Nicotinell
Participants will be administered with 2 mg coated fruit flavor gum of Nicotinell
|
Other: Treatment A: Treatment C:Treatment B
Participants will be administered with Treatment A (Nicorette 2 mg coated mint gum) followed by Treatment C (Nicotinell 2 mg coated fruit flavor gum) followed by Treatment B (Nicotinell 2 mg coated mint gum).
Administration of each treatment will be separated by clinical furlough period of at least 7 days and not more than 10 days.
|
Participants will be administered with 2 mg coated mint gum of Nicorette
Participants will be administered with 2 mg coated mint gum of Nicotinell
Participants will be administered with 2 mg coated fruit flavor gum of Nicotinell
|
Other: Treatment B:Treatment A: Treatment C
Participants will be administered with Treatment B (Nicotinell 2 mg coated mint gum) followed by Treatment A (Nicorette 2 mg coated mint gum) followed by Treatment C (Nicotinell 2 mg coated fruit flavor gum).
Administration of each treatment will be separated by clinical furlough period of at least 7 days and not more than 10 days.
|
Participants will be administered with 2 mg coated mint gum of Nicorette
Participants will be administered with 2 mg coated mint gum of Nicotinell
Participants will be administered with 2 mg coated fruit flavor gum of Nicotinell
|
Other: Treatment C:Treatment B:Treatment A
Participants will be administered with Treatment C (Nicotinell 2 mg coated fruit flavor gum) followed by Treatment B (Nicotinell 2 mg coated mint gum) followed by Treatment A (Nicorette 2 mg coated mint gum).
Administration of each treatment will be separated by clinical furlough period of at least 7 days and not more than 10 days.
|
Participants will be administered with 2 mg coated mint gum of Nicorette
Participants will be administered with 2 mg coated mint gum of Nicotinell
Participants will be administered with 2 mg coated fruit flavor gum of Nicotinell
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area under the curve from time zero to last sampling time [AUC(0-t)]
Time Frame: 2 days
|
AUC(0-t) will be calculated using the trapezoidal rule.
Twenty (20) blood samples will be collected at baseline and multiple timepoints following study drug administration.
|
2 days
|
Area under the curve from time zero extrapolated to infinity [AUC(0-inf)]
Time Frame: 2 days
|
The area under the plasma concentration versus time curve will be calculated from time 0 to infinity where AUC = AUClast + Clast/λz Clast is the concentration at the last measurable sampling time point and λz is the terminal elimination rate constant.
Twenty (20) blood samples will be collected at baseline and multiple timepoints following study drug administration.
|
2 days
|
Maximum plasma concentration (Cmax)
Time Frame: 2 days
|
Cmax will be obtained graphically from the plasma concentration over time profile.
Twenty (20) blood samples will be collected at baseline and multiple timepoints following study drug administration.
|
2 days
|
Time to reach maximum plasma concentration (Tmax)
Time Frame: 2 days
|
Tmax will be obtained graphically from the plasma concentration over time profile.
Twenty (20) blood samples will be collected at baseline and multiple timepoints following study drug administration.
|
2 days
|
Termination rate constant (Lambda_z)
Time Frame: 2 days
|
Lambda_z will be computed as the slope of the regression line of ln (C(t)) on time.
Twenty (20) blood samples will be collected at baseline and multiple timepoints following study drug administration.
|
2 days
|
Elimination half life (t1/2)
Time Frame: 2 days
|
T1/2 will be computed as T1/2 = 0.693/ λz.
Twenty (20) blood samples will be collected at baseline and multiple timepoints following study drug administration.
|
2 days
|
Systemic clearance (CL/F)
Time Frame: 2 days
|
CL/F will be calculated as the Dose/AUCinf, where Dose is the actual nicotine dose released.
Twenty (20) blood samples will be collected at baseline and multiple timepoints following study drug administration.
|
2 days
|
Apparent volume of distribution (Vd/F)
Time Frame: 2 days
|
Vd/F will be determined by the following equation: Vz/F = Dose/(lambda_z · AUCinf), where Dose is the actual nicotine dose released.
Twenty (20) blood samples will be collected at baseline and multiple timepoints following study drug administration.
|
2 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 11, 2016
Primary Completion (Actual)
June 12, 2016
Study Completion (Actual)
June 12, 2016
Study Registration Dates
First Submitted
February 18, 2016
First Submitted That Met QC Criteria
February 18, 2016
First Posted (Estimate)
February 23, 2016
Study Record Updates
Last Update Posted (Actual)
December 19, 2017
Last Update Submitted That Met QC Criteria
December 18, 2017
Last Verified
December 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Substance-Related Disorders
- Tobacco Use Disorder
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Cholinergic Agents
- Ganglionic Stimulants
- Nicotinic Agonists
- Cholinergic Agonists
- Nicotine
Other Study ID Numbers
- 204979
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tobacco Use Disorder
-
Washington University School of MedicineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Nicotine Dependence | Tobacco Dependence | Smoking, Tobacco | Nicotine Use Disorder | Nicotine Dependence, Cigarettes | Smoking, Cigarette | Nicotine Dependence Tobacco Product | Tobacco; Use, Rehabilitation | Smoking (Tobacco) Addiction and other conditionsUnited States
-
Johns Hopkins UniversityNational Institute on Drug Abuse (NIDA)RecruitingTobacco Use | Tobacco Smoking | Tobacco Use Disorder | Tobacco Use Cessation | Tobacco DependenceUnited States
-
Harvard School of Public Health (HSPH)Beacon Communities; The Community BuildersEnrolling by invitationTobacco Use | Tobacco Smoking | Tobacco Use Disorder | Tobacco Use Cessation | Second Hand Tobacco SmokeUnited States
-
University of California, San FranciscoNational Institute on Minority Health and Health Disparities (NIMHD)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Disorder | Tobacco Use Cessation | Tobacco Dependence | Smoking, Tobacco | Smoking, CigaretteUnited States
-
University of California, San FranciscoTobacco Related Disease Research ProgramCompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Disorder | Tobacco Use Cessation | Tobacco Dependence | Smoking, Tobacco | Smoking, CigaretteUnited States
-
New York State Psychiatric InstituteTerminatedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Disorder | Nicotine Dependence | Cigarette Smoking | Tobacco Dependence | Nicotine Use Disorder | Smoking, CigaretteUnited States
-
Rutgers, The State University of New JerseyNational Institute on Drug Abuse (NIDA)CompletedSchizophrenia | Schizoaffective Disorder | Tobacco Use | Tobacco Smoking | Tobacco Use Disorder | Tobacco Use CessationUnited States
-
University of PennsylvaniaFood and Drug Administration (FDA)Completed
-
University of Kansas Medical CenterCompletedTobacco Use Disorder/Cigarette SmokingUnited States
-
Ottawa Hospital Research InstituteCompletedTobacco Use Disorder | Tobacco Use Cessation | Tobacco Dependence
Clinical Trials on Treatment A: Nicorette 2 mg coated mint gum
-
McNeil ABJanssen (China) Research & Development CenterCompleted
-
McNeil ABCompletedTobacco DependenceSweden
-
McNeil ABCompleted
-
US Department of Veterans AffairsTerminated
-
McNeil ABCompleted
-
University of OklahomaCompleted
-
Merck Sharp & Dohme LLCCompletedHuman Immunodeficiency Virus-1 (HIV-1)
-
PfizerCompletedBiological AvailabilityUnited States
-
Janssen Research & Development, LLCCompleted
-
Washington State UniversityNational Center for Complementary and Integrative Health (NCCIH); Office of...Active, not recruitingInteraction Drug FoodUnited States